3 ASX medical tech shares surging higher today

Here are 3 ASX shares in the fast-growing medical tech sector that have seen gains of around 5% so far today.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The medical technology sector is a fast-growing sector both domestically on the ASX and internationally. Here are 3 ASX med-tech shares that have seen gains of around 5% so far today.

Polynovo Ltd (ASX: PNV)

PolyNovo develops innovative medical devices including its patented polymer technology NovoSorb. The PolyNovo share price is up by 4.5% today at the time of writing.

NovoSorb BTM works to regenerate the dermis, which is the underlying structure of the skin, providing a synthetic scaffold that blood vessels can migrate into.

The NovoSorb product has been recording sales at a record pace in recent months. Notably, Polynovo reported $2 million of monthly sales in December 2019, up 134% on December 2018.

In January, PolyNovo launched its product in the UK, Germany, Austria, and Switzerland, and reported impressive clinical results. Sales in the US continue to be strong.

PolyNovo shares surged higher again last week after CEO Paul Brennan outlined plans for further aggressive growth, with company strategy focused on reinvesting money back into the business to drive top-line growth.

Pro Medicus Limited (ASX: PME)

The Pro Medicus share price is up by 5.33% today at the time of writing. Pro Medicus provides healthcare imaging software and services to hospitals, diagnostic imaging groups and other health-related entities in Australia, North America and Europe.

Pro Medicus has been one of the best-performing ASX shares over the past decade, with its share price rising from under $1 prior to 2014 to reach an all-time high of $38.39 mid last year. Shares have pulled back since then, currently trading at $27.84 per share.

Pro Medicus' recent growth has been driven by new contracts, no debt, a rising dividend, and emerging market opportunities. In FY19, the company delivered a 92% increase in revenue to $50.1 million. This impressive result was driven by strong growth across its business during the period which saw revenue growth of 102% in Europe, 30% in Australia, and 42% in North America. 

Medadvisor Ltd (ASX: MDR)

MedAdvisor is an Australian software systems developer whose shares are currently up by 5.05% today.

The company's free app connects to pharmacy dispensing systems to automatically retrieve medication records and also drives a training, information and reminder system to ensure correct and reliable medication use.

In Australia, MedAdvisor has worked with over 20 different digital health program clients to fund digital and in-pharmacy programs designed to help patients take their medication.

In January, Medadvisor announced it had signed its second agreement in the United States. The agreement provides medication education programs for top 10 global pharmaceutical companies through its strategic partner Adheris Health. With this, MedAdvisor will execute four pilot programs through a total of up to 4,000 US pharmacies in partnership with Adheris Health.

Phil Harpur has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. recommends Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia has recommended MedAdvisor. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Smiling man with phone in wheelchair watching stocks and trends on computer
Share Market News

5 things to watch on the ASX 200 on Monday

A good start to the week is expected for Aussie investors. Here's what to watch.

Read more »

A businessman compares the growth trajectory of property versus shares.
Opinions

What's the outlook for shares vs. property in 2025?

The experts have put out their new year predictions...

Read more »

a man sits at his desk wearing a business shirt and tie and has a hearty laugh at something on his mobile phone.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A young man pointing up looking amazed, indicating a surging share price movement for an ASX company
Broker Notes

These ASX 200 shares could rise 20% to 40% in 2025

Analysts are tipping these shares to deliver huge returns for investors next year.

Read more »

A transport worker walks alongside a stack of containers at a port.
Share Market News

Here's how the ASX 200 market sectors stacked up last week

Industrials came out best amid another bad week for the ASX 200, which fell 2.47% to 8,067 points.

Read more »

Cheerful boyfriend showing mobile phone to girlfriend in dining room. They are spending leisure time together at home and planning their financial future.
Opinions

My ASX share portfolio is up 30% this year! Here's my plan for 2025

The best investing plans shouldn't need too many updates.

Read more »

Animation of a man measuring a percentage sign, symbolising rising interest rates.
Share Market News

Here's when Westpac says the RBA will cut interest rates in 2025

Will the RBA finally take interest rates lower in 2025? Let's see what is being forecast.

Read more »

Shares vs property concept illustrated by graphs in the background and house models on coins.
Share Market News

Shares vs. property: Biggest investment trends of 2024

As another year of investing draws to a close, we review the most significant trends.

Read more »